XOMA (NASDAQ:XOMA) Shares Pass Above 200 Day Moving Average of $16.86

XOMA Co. (NASDAQ:XOMAGet Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $16.86 and traded as high as $21.11. XOMA shares last traded at $20.33, with a volume of 20,361 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $74.00 price objective on shares of XOMA in a research note on Friday, December 22nd.

Get Our Latest Analysis on XOMA

XOMA Trading Down 2.3 %

The stock has a market capitalization of $233.59 million, a P/E ratio of -7.23 and a beta of 0.55. The stock’s 50 day simple moving average is $18.82 and its 200 day simple moving average is $16.86.

XOMA (NASDAQ:XOMAGet Free Report) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.12). XOMA had a negative return on equity of 24.70% and a negative net margin of 636.27%. The firm had revenue of $0.83 million during the quarter, compared to analyst estimates of $1.47 million. On average, sell-side analysts expect that XOMA Co. will post -2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA

Several large investors have recently added to or reduced their stakes in XOMA. UBS Group AG raised its holdings in shares of XOMA by 9,318.8% during the third quarter. UBS Group AG now owns 1,507 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,491 shares during the period. Barclays PLC acquired a new position in XOMA in the second quarter valued at approximately $28,000. BNP Paribas Arbitrage SNC acquired a new position in XOMA in the second quarter valued at approximately $36,000. BNP Paribas Financial Markets grew its holdings in shares of XOMA by 118.3% during the fourth quarter. BNP Paribas Financial Markets now owns 2,277 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 1,234 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of XOMA by 40.7% during the 4th quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 689 shares during the period. 65.35% of the stock is currently owned by institutional investors.

About XOMA

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Featured Articles

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.